Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky

This article was originally published in Start Up

Executive Summary

Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.


Related Content

Pipeline Update: New Antifungals Sprout In Warmer Regulatory Climate
Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
Point-Of-Care Testing Stirs Anew
Spero Therapeutics LLC
Nosopharm SAS
EnBiotix Inc.
Antibiotic Drug Push By Administration Could Include BARDA Incubator
Economic Model For Antibiotics Is Broken, AstraZeneca’s Rex Says
Arsanis Biosciences GMBH
AvidBiotics Corp.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts